Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

112 trials

NCT07437963
Recruiting
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Phase 1/2 · United States · 4 sites
Registry update: 6 Nov 2026
NCT07635056
Recruiting
Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
Phase 2 · United States · 1 site
Registry update: 24 Aug 2026
NCT07358260
Recruiting
B7-H3.CD28Z.CART in Solid Tumors
Phase 1 · United States · 1 site
Registry update: 3 Sept 2026
NCT07767630
Recruiting
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
Early phase 1 · China · 1 site
Registry update: 21 Aug 2026
NCT07211737
Recruiting
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Phase 1 · United States · 1 site
Registry update: 21 Jul 2026
NCT07688252
Recruiting
Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma
Phase 1 · Taiwan · 2 sites
Registry update: 6 Oct 2026
NCT07537400
Recruiting
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Phase 2 · Israel · 1 site
Registry update: 17 Sept 2026
2024-514089-37-00
Recruiting
Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
Phase 2 · Netherlands · 1 site
Registry update: 30 Apr 2026
NCT07584499
Recruiting
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
Phase 1 · China · 1 site
Registry update: 13 May 2026
NCT06465199
Recruiting
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Phase 1/2 · United States · 14 sites
Registry update: 3 Sept 2026
NCT07549321
Recruiting
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Phase 2/3 · Canada, Germany, Denmark, Spain, France, United Kingdom, United States · 20 sites
Registry update: 3 Nov 2026
NCT07502287
Recruiting
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Phase 1/2 · China · 1 site
Registry update: 30 Mar 2026
NCT06625190
Recruiting
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Phase 1/2 · United States · 1 site
Registry update: 30 Jun 2026
NCT07172958
Recruiting
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Phase 1 · United States · 2 sites
Registry update: 13 Aug 2026
NCT07318831
Recruiting
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Phase 2 · China · 1 site
Registry update: 1 Oct 2026
NCT07375563
Recruiting
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Phase 3 · Russia · 1 site
Registry update: 29 Jan 2026
NCT07085338
Recruiting
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
Phase 2 · United States · 5 sites
Registry update: 7 Aug 2026
NCT07399821
Recruiting
An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
Phase 1/2 · Netherlands · 1 site
Registry update: 10 Feb 2026
Conflicting statuses (not updated in the registry for 8 months)
NCT06995872
Recruiting
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Phase 1 · United States · 1 site
Registry update: 21 Oct 2026
2025-521497-34-00
Recruiting
Long-term follow-up of patients treated with GD2IL18CART
Phase 1 · Germany · 4 sites
Registry update: 23 Sept 2026

Ordered by registry start date. Freshness and sponsorship never change the order.